Loading
Orthopedic Infections and Treatments · Journal article
Frontiers in Cell and Developmental Biology · August 3, 2026
Raises a question worth testing. It does not answer one.
This is a narrative mini-review that outlines emerging biomaterial design strategies for osteomyelitis treatment, including local antimicrobial delivery, photothermal therapy, and immunomodulation approaches. The work is conceptual and identifies design principles and clinical translation challenges rather than reporting new empirical evidence or clinical outcomes.
Journal article. Patients with osteomyelitis (infectious bone disease).
Conventional osteomyelitis treatments (systemic antibiotics, surgical debridement, antibiotic-loaded bone cement) are limited by insufficient drug penetration, nondegradable materials, need for secondary surgery, and recurrence risk Emerging biomaterials enable local delivery of antimicrobial agents, antimicrobial peptides, metal ions, or gaseous molecules, often combined with photothermal therapy, sonodynamic therapy, pH/enzyme-responsive systems, and immunomodulation
No specific efficacy, safety, or outcome metrics provided for any biomaterial strategy
This review identifies design principles for next-generation biomaterials rather than providing evidence for immediate clinical application. Clinicians should view this as a landscape of emerging strategies under investigation, not as comparative evidence supporting any particular intervention.
This is a narrative review summarizing design strategies and emerging biomaterial approaches for osteomyelitis; it raises questions about clinical translation rather than reporting new evidence or trials.
This review identifies design principles for next-generation biomaterials rather than providing evidence for immediate clinical application. Clinicians should view this as a landscape of emerging strategies under investigation, not as comparative evidence supporting any particular intervention.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Osteomyelitis (OM) is an infectious disease caused by the invasion of bone tissue by pathogenic microorganisms. It is frequently associated with biofilm formation, residual sequestra, local ischemia and hypoxia, elevated oxidative stress, and immune dysfunction. Conventional treatments rely on systemic antibiotics, surgical debridement, antibiotic-loaded bone cement, and bone transport techniques. Although these approaches can control infection in some cases, they remain limited by insufficient drug penetration, nondegradable materials, the need for secondary surgery, difficulty in repairing bone defects, and the risk of recurrence. In recent years, emerging biomaterials have provided new therapeutic strategies for OM by enabling the local delivery of antimicrobial agents, antimicrobial peptides, metal ions, or gaseous molecules, often in combination with photothermal therapy, sonodynamic therapy, pH/enzyme-responsive systems, and immunomodulation. The aim of this mini-review is to briefly summarize the pathological features of OM, outline the major design strategies of biomaterials currently used for OM treatment, and discuss the challenges associated with their clinical translation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.